Immupharma PLC 2020 AGM -- ALL RESOLUTIONS PASSED (3880Q)
18 Junio 2020 - 5:31AM
UK Regulatory
TIDMIMM
RNS Number : 3880Q
Immupharma PLC
18 June 2020
18 June 2020
ImmuPharma PLC
("ImmuPharma" or the "Company")
2020 ANNUAL GENERAL MEETING - ALL RESOLUTIONS PASSED
ImmuPharma PLC (LSE:IMM | Euronext Growth Brussels: ALIMM) , the
specialist drug discovery and development company, held its AGM
earlier today, in accordance with COVID-19 guidance. The Company is
pleased to announce that all resolutions were duly passed, by way
of a poll.
-Ends-
For further information please contact:
ImmuPharma PLC ( www.immupharma.com )
Tim McCarthy, Chairman + 44 (0) 207 152 4080
Dimitri Dimitriou, Chief Executive Officer
Lisa Baderoon, Head of Investor Relations + 44 (0) 7721 413496
SPARK Advisory Partners Limited (NOMAD)
Neil Baldwin +44 (0) 203 368 3550
Stanford Capital Partners (Joint Broker)
Patrick Claridge, John Howes +44 (0) 203 815 8880
SI Capital (Joint Broker)
Nick Emerson +44 (0) 1483 413500
4Reliance (Euronext Growth Listing Sponsor) +32 (0) 2 747 02 60
Jean-Charles Snoy
Degroof Petercam (Liquidity Provider) +32 (0) 2 287 95 34
Erik De Clippel
Backstage Communication
Olivier Duquaine +32 (0) 477 504 784
Gunther De Backer +32 (0) 475 903 909
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a
specialty biopharmaceutical company that discovers and develops
peptide-based therapeutics. The Company's portfolio includes novel
peptide therapeutics for autoimmune diseases, metabolic diseases,
anti-infectives and cancer. The lead program, Lupuzor(TM), is a
first-in class autophagy immunomodulator which is in Phase III for
the treatment of lupus and preclinical analysis suggest therapeutic
activity for many other autoimmune diseases that share the same
autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals
signed on 28 November 2019, an exclusive licence and development
agreement and trademark agreement for Lupuzor(TM) to fund a new
international Phase III trial for Lupuzor(TM) and commercialise in
the US. For additional information about ImmuPharma please visit
www.immupharma.com . ImmuPharma's LEI (Legal Entity Identifier)
code: 213800VZKGHXC7VUS895.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
RAGZZGMVGRNGGZM
(END) Dow Jones Newswires
June 18, 2020 06:31 ET (10:31 GMT)
Immupharma (LSE:IMM)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Immupharma (LSE:IMM)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024